Top

Published in:

Open Access 01-07-2017

T2 mapping and T2* imaging in heart failure

Authors: A.S. Lota, P.D. Gatehouse, R.H. Mohiaddin

Published in: Heart Failure Reviews | Issue 4/2017

Abstract

Cardiovascular magnetic resonance (CMR) is a versatile imaging modality that enables aetiological assessment and provides additional information to that of standard echocardiography in a significant proportion of patients with heart failure. In addition to highly accurate and reproducible assessment of ventricular volumes and replacement fibrosis, multiparametric mapping techniques have rapidly evolved to further expand the diagnostic and prognostic applications in various conditions ranging from acute inflammatory and ischaemic cardiomyopathy, to cardiac involvement in systemic diseases such as sarcoidosis and iron overload cardiomyopathy. In this review, we discuss the established role of T2* imaging and rapidly evolving clinical applications of myocardial T2 mapping as quantitative adjuncts to established qualitative imaging techniques.

Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S (2009) The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol 54(15):1407–1424. doi:10.1016/j.jacc.2009.04.094 CrossRefPubMed

Sado DM, Hasleton JM, Herrey AS, Moon JC (2011) CMR in heart failure. Cardiol Res Pract 2011:739157. doi:10.4061/2011/739157 PubMedPubMedCentral

Fung BM (1986) Nuclear magnetic resonance study of water interactions with proteins, biomolecules, membranes, and tissues. Methods Enzymol 127:151–161CrossRefPubMed

Fung BM, Puon PS (1981) Nuclear magnetic resonance transverse relaxation in muscle water. Biophys J 33(1):27–37. doi:10.1016/s0006-3495(81)84870-9 CrossRefPubMedPubMedCentral

Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O’Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK (2013) Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309(9):896–908. doi:10.1001/jama.2013.1363 CrossRefPubMed

Higgins CB, Herfkens R, Lipton MJ, Sievers R, Sheldon P, Kaufman L, Crooks LE (1983) Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol 52(1):184–188CrossRefPubMed

Eitel I, Friedrich MG (2011) T2-weighted cardiovascular magnetic resonance in acute cardiac disease. J Cardiovasc Magn Reson 13(1):13–13. doi:10.1186/1532-429X-13-13 CrossRefPubMedPubMedCentral

Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ (2011) On T2* magnetic resonance and cardiac iron. Circulation 123(14):1519–1528. doi:10.1161/circulationaha.110.007641 CrossRefPubMedPubMedCentral

Kellman P, Aletras AH, Mancini C, McVeigh ER, Arai AE (2007) T2-prepared SSFP improves diagnostic confidence in edema imaging in acute myocardial infarction compared to turbo spin echo. Magn Reson Med 57(5):891–897. doi:10.1002/mrm.21215 CrossRefPubMedPubMedCentral

10.

Giri S, Chung Y-C, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP (2009) T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson 11(1):56. doi:10.1186/1532-429x-11-56 CrossRefPubMedPubMedCentral

11.

von Knobelsdorff-Brenkenhoff F, Prothmann M, Dieringer MA, Wassmuth R, Greiser A, Schwenke C, Niendorf T, Schulz-Menger J (2013) Myocardial T1 and T2 mapping at 3 T: reference values, influencing factors and implications. J Cardiovasc Magn Reson 15(1):53. doi:10.1186/1532-429x-15-53 CrossRef

12.

Thavendiranathan P, Walls M, Giri S, Verhaert D, Rajagopalan S, Moore S, Simonetti OP, Raman SV (2012) Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping. Circ Cardiovasc Imaging 5(1):102–110. doi:10.1161/CIRCIMAGING.111.967836 CrossRefPubMed

13.

Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR (1994) Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331(9):574–578. doi:10.1056/nejm199409013310903 CrossRefPubMed

14.

Henry WL, Nienhuis AW, Wiener M, Miller DR, Canale VC, Piomelli S (1978) Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition. Am J Med 64(4):547–555CrossRefPubMed

15.

Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22(23):2171–2179CrossRefPubMed

16.

Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ (2009) Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120(20):1961–1968. doi:10.1161/CIRCULATIONAHA.109.874487 CrossRefPubMedPubMedCentral

17.

Baksi AJ, Pennell DJ (2014) Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major. Front Pharmacol 5:217. doi:10.3389/fphar.2014.00217 CrossRefPubMedPubMedCentral

18.

Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet (London, England) 360(9332):516–520CrossRef

19.

Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ (2004) Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127(3):348–355. doi:10.1111/j.1365-2141.2004.05202.x CrossRefPubMed

20.

Carpenter JP, Roughton M, Pennell DJ (2013) International survey of T2* cardiovascular magnetic resonance in beta-thalassemia major. Haematologica 98(9):1368–1374. doi:10.3324/haematol.2013.083634 CrossRefPubMedPubMedCentral

21.

Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam WWM, Au WY, Chu WCW, Chan G, Galanello R, Matta G, Fogel M, Cohen AR, Tan RS, Chen K, Ng I, Lai A, Fucharoen S, Laothamata J, Chuncharunee S, Jongjirasiri S, Firmin DN, Smith GC, Pennell DJ (2010) International reproducibility of single breath-hold T2* magnetic resonance for cardiac and liver iron assessment among five thalassemia centers. Journal of magnetic resonance imaging : JMRI 32(2):315–319. doi:10.1002/jmri.22245 CrossRefPubMedPubMedCentral

22.

Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ (2008) Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 10:42. doi:10.1186/1532-429x-10-42 CrossRefPubMedPubMedCentral

23.

Baksi AJ, Pennell DJ (2013) T1 Mapping in heart failure. From technique to prognosis, toward altering outcome. Circ Cardiovasc Imaging 6(6):861–863. doi:10.1161/circimaging.113.001178

24.

Greulich S, Ferreira VM, Dall’Armellina E, Mahrholdt H (2015) Myocardial inflammation—are we there yet? Current Cardiovascular Imaging Reports 8(3):6. doi:10.1007/s12410-015-9320-6 CrossRefPubMedPubMedCentral

25.

Puranik R, Chow CK, Duflou JA, Kilborn MJ, McGuire MA (2005) Sudden death in the young. Heart Rhythm 2(12):1277–1282. doi:10.1016/j.hrthm.2005.09.008 CrossRefPubMed

26.

Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H (2012) Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 59(18):1604–1615. doi:10.1016/j.jacc.2012.01.007 CrossRefPubMed

27.

Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U (2006) Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114(15):1581–1590. doi:10.1161/circulationaha.105.606509 CrossRefPubMed

28.

Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53(17):1475–1487. doi:10.1016/j.jacc.2009.02.007 CrossRefPubMedPubMedCentral

29.

Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, Klingel K, Kandolf R, Sechtem U, Cooper LT, Bohm M (2012) Update on myocarditis. J Am Coll Cardiol 59(9):779–792. doi:10.1016/j.jacc.2011.09.074 CrossRefPubMed

30.

Hauck AJ, Kearney DL, Edwards WD (1989) Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 64(10):1235–1245CrossRefPubMed

31.

Stiermaier T, Fohrenbach F, Klingel K, Kandolf R, Boudriot E, Sandri M, Linke A, Rommel KP, Desch S, Schuler G, Thiele H, Lurz P (2017) Biventricular endomyocardial biopsy in patients with suspected myocarditis: feasibility, complication rate and additional diagnostic value. Int J Cardiol 230:364–370. doi:10.1016/j.ijcard.2016.12.103 CrossRefPubMed

32.

Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648, 2648a-2648d. doi:10.1093/eurheartj/eht210 CrossRefPubMed

33.

Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, Adam G, Blankenberg S, Muellerleile K (2015) Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging 8(6):e003073. doi:10.1161/CIRCIMAGING.114.003073

34.

Lurz P, Luecke C, Eitel I, Fohrenbach F, Frank C, Grothoff M, de Waha S, Rommel KP, Lurz JA, Klingel K, Kandolf R, Schuler G, Thiele H, Gutberlet M (2016) Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-trial. J Am Coll Cardiol 67(15):1800–1811. doi:10.1016/j.jacc.2016.02.013 CrossRefPubMed

35.

Baeßler B, Schaarschmidt F, Dick A, Stehning C, Schnackenburg B, Michels G, Maintz D, Bunck AC (2015) Mapping tissue inhomogeneity in acute myocarditis: a novel analytical approach to quantitative myocardial edema imaging by T2-mapping. J Cardiovasc Magn Reson 17(1):115. doi:10.1186/s12968-015-0217-y CrossRefPubMedPubMedCentral

36.

Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ (2005) Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45(10):1683–1690. doi:10.1016/j.jacc.2005.01.047 CrossRefPubMed

37.

Fabre A, Sheppard MN (2006) Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 92(3):316–320. doi:10.1136/hrt.2004.045518 CrossRefPubMed

38.

Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H, Amaki M, Kanzaki H, Okamura H, Kamakura S, Shimizu W, Anzai T, Kitakaze M (2014) Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100(15):1165–1172. doi:10.1136/heartjnl-2013-305187 CrossRefPubMed

39.

Constantine G, Shan K, Flamm SD, Sivananthan MU (2004) Role of MRI in clinical cardiology. Lancet (London, England) 363(9427):2162–2171. doi:10.1016/s0140-6736(04)16509-4 CrossRef

40.

Freeman AM, Curran-Everett D, Weinberger HD, Fenster BE, Buckner JK, Gottschall EB, Sauer WH, Maier LA, Hamzeh NY (2013) Predictors of cardiac sarcoidosis using commonly available cardiac studies. Am J Cardiol 112(2):280–285. doi:10.1016/j.amjcard.2013.03.027 CrossRefPubMed

41.

Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, Miura M, Sakaue S, Tamaki N, Nishimura M (2008) Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 35(5):933–941. doi:10.1007/s00259-007-0650-8 CrossRefPubMed

42.

Crouser ED, Ono C, Tran T, He X, Raman SV (2014) Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med 189(1):109–112. doi:10.1164/rccm.201309-1668LE PubMedPubMedCentral

43.

Wicks E, Menezes L, Pantazis A, Mohiddin S, Porter J, Booth H, Sekhri N, O’Meara C, Moon J, McKenna W, Groves A, Elliott P (2014) 135 novel hybrid positron emission tomography - magnetic resonance (PET-MR) multi-modality inflammatory imaging has improved diagnostic accuracy for detecting cardiac sarcoidosis. Heart 100(Suppl 3):A80. doi:10.1136/heartjnl-2014-306118.135 CrossRef

44.

Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J, Messroghli D, Dietz R (2008) The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol 51(16):1581–1587. doi:10.1016/j.jacc.2008.01.019 CrossRefPubMed

45.

Abdel-Aty H, Cocker M, Meek C, Tyberg JV, Friedrich MG (2009) Edema as a very early marker for acute myocardial ischemia: a cardiovascular magnetic resonance study. J Am Coll Cardiol 53(14):1194–201. doi:10.1016/j.jacc.2008.10.065

46.

Wince WB, Kim RJ (2010) Molecular imaging: T2-weighted CMR of the area at risk—a risky business? Nat Rev Cardiol 7(10):547–549CrossRefPubMed

47.

Hammer-Hansen S, Ugander M, Hsu L-Y, Taylor J, Thune JJ, Køber L, Kellman P, Arai AE (2014) Distinction of salvaged and infarcted myocardium within the ischaemic area-at-risk with T2 mapping. European Heart Journal - Cardiovascular Imaging 15(9):1048–1053. doi:10.1093/ehjci/jeu073 CrossRefPubMedPubMedCentral

48.

Zia MI, Roifman I, Ghugre NR, Ignatius AJ, Strauss BH, Dick A, Wright GA, Connelly KA (2015) Prognostic value of myocardial T2 mapping post reperfused acute myocardial infarction. J Cardiovasc Magn Reson 17(Suppl 1):P150. doi:10.1186/1532-429X-17-S1-P150 CrossRefPubMedCentral

49.

Hamirani YS, Wong A, Kramer CM, Salerno M (2014) Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. JACC Cardiovasc Imaging 7(9):940–952. doi:10.1016/j.jcmg.2014.06.012 CrossRefPubMedPubMedCentral

50.

Eitel I, Kubusch K, Strohm O, Desch S, Mikami Y, de Waha S, Gutberlet M, Schuler G, Friedrich MG, Thiele H (2011) Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. Circ Cardiovasc Imaging 4(4):354–362. doi:10.1161/circimaging.110.960500 CrossRefPubMed

51.

Jackowski C, Christe A, Sonnenschein M, Aghayev E, Thali MJ (2006) Postmortem unenhanced magnetic resonance imaging of myocardial infarction in correlation to histological infarction age characterization. Eur Heart J 27(20):2459–2467. doi:10.1093/eurheartj/ehl255 CrossRefPubMed

52.

Kali A, Tang RLQ, Kumar A, Min JK, Dharmakumar R (2013) Detection of acute reperfusion myocardial hemorrhage with cardiac MR imaging: T2 versus T2*. Radiology 269(2):387–395. doi:10.1148/radiol.13122397 CrossRefPubMedPubMedCentral

53.

Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E (2016) Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 18(1):8–27. doi:10.1002/ejhf.424 CrossRefPubMed

54.

Abdel-Aty H, Cocker M, Friedrich MG (2009) Myocardial edema is a feature of Tako-Tsubo cardiomyopathy and is related to the severity of systolic dysfunction: insights from T2-weighted cardiovascular magnetic resonance. Int J Cardiol 132(2):291–293. doi:10.1016/j.ijcard.2007.08.102 CrossRefPubMed

55.

Vermes E, Pericart L, Pucheux J, Delhommais A, Alison D, Genee O (2015) T2-mapping and T1-mapping detect myocardial involvement in Tako-Tsubo cardiomyopathy: a preliminary experience. J Cardiovasc Magn Reson 17(Suppl 1):P354–P354. doi:10.1186/1532-429X-17-S1-P354 CrossRefPubMedCentral

56.

Marie PY, Angioi M, Carteaux JP, Escanye JM, Mattei S, Tzvetanov K, Claudon O, Hassan N, Danchin N, Karcher G, Bertrand A, Walker PM, Villemot JP (2001) Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. J Am Coll Cardiol 37(3):825–831CrossRefPubMed

57.

Butler CR, Savu A, Bakal JA, Toma M, Thompson R, Chow K (2015) Correlation of cardiovascular MRI findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection cardiovascular MRI and heart transplant rejection. J Heart Lung Transplant 34:643–650. doi:10.1016/j.healun.2014.12.020

58.

Usman AA, Taimen K, Wasielewski M, McDonald J, Shah S, Giri S, Cotts W, McGee E, Gordon R, Collins JD, Markl M, Carr JC (2012) Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging 5(6):782–790. doi:10.1161/circimaging.111.971101 CrossRefPubMed

59.

Bonnemains L, Cherifi A, Girerd N, Odille F, Felblinger J (2015) Design of the DRAGET Study: a multicentre controlled diagnostic study to assess the detection of acute rejection in patients with heart transplant by means of T2 quantification with MRI in comparison to myocardial biopsies. BMJ Open 5(10):e008963. doi:10.1136/bmjopen-2015-008963

60.

Thavendiranathan P, Amir E, Bedard P, Crean A, Paul N, Nguyen ET, Wintersperger BJ (2014) Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab. J Cardiovasc Magn Reson 16(1):P273. doi:10.1186/1532-429x-16-s1-p273 CrossRefPubMedCentral

61.

Smith GC, Carpenter JP, He T, Alam MH, Firmin DN, Pennell DJ (2011) Value of black blood T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 13(1):21. doi:10.1186/1532-429x-13-21 CrossRefPubMedPubMedCentral

Title: T2 mapping and T2* imaging in heart failure
Authors: A.S. Lota
P.D. Gatehouse
R.H. Mohiaddin
Publication date: 01-07-2017
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 4/2017
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-017-9616-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

T2 mapping and T2* imaging in heart failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Strain imaging using cardiac magnetic resonance

Introduction to the Special Issue: Myocardial Imaging in Heart Failure

T1 mapping in cardiac MRI

Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies

Principals and clinical applications of magnetic resonance cardiac spectroscopy in heart failure

Assessment of myocardial blood flow and coronary flow reserve with positron emission tomography in ischemic heart disease: current state and future directions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page